SPOTLIGHT -
Jamie Myers Describes the Design of Her CRCI Study
Jamie Myers Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study
Read More
Jamie Myers Explains Results From Her CRCI Study
Jamie Myers Explains Results From Her Chemotherapy-Related Cognitive Impairment Study
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
